Rein Therapeutics (NASDAQ:RNTX) Research Coverage Started at HC Wainwright

HC Wainwright began coverage on shares of Rein Therapeutics (NASDAQ:RNTX) in a research note published on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for Rein Therapeutics’ Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($0.97) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at ($1.03) EPS.

Separately, Brookline Capital Management lowered Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 19th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Rein Therapeutics Trading Up 6.2%

Shares of Rein Therapeutics stock opened at $1.19 on Monday. The firm has a market capitalization of $27.74 million, a P/E ratio of -0.44 and a beta of 1.13. The business has a fifty day simple moving average of $1.23 and a two-hundred day simple moving average of $1.58. Rein Therapeutics has a 12 month low of $1.04 and a 12 month high of $4.40.

Rein Therapeutics (NASDAQ:RNTX) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.06). Analysts predict that Rein Therapeutics will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On Rein Therapeutics

Several large investors have recently modified their holdings of the stock. Blair William & Co. IL purchased a new position in shares of Rein Therapeutics in the 2nd quarter worth about $33,000. Meridian Wealth Advisors LLC bought a new stake in Rein Therapeutics in the 2nd quarter worth about $40,000. Exencial Wealth Advisors LLC bought a new stake in Rein Therapeutics in the 2nd quarter worth about $43,000. Chicago Partners Investment Group LLC bought a new stake in Rein Therapeutics in the 2nd quarter worth about $64,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in Rein Therapeutics in the 2nd quarter worth about $68,000. Hedge funds and other institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Company Profile

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.